Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)
- Conditions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Advenchen Laboratories, LLC
- Registration Number
- NCT05612191
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 325
- Registration Number
- NCT03016819
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUniversity of California Los Angeles, Los Angeles, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 294
- Registration Number
- NCT02584478
- Locations
- ๐จ๐ณ
The First Hospital of China Medical University, Shenyang, Shenyang, China
๐จ๐ณObstetrics&Gynecology Hospital of Fudan University, Shanghai, Yangpu District, China
๐จ๐ณChongqing University Cancer Hospital, Chongqing, China
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02558348
- Locations
- ๐บ๐ธ
University of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath